U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971380) titled 'Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis' on April 23.
Brief Summary: A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma, Refractory to Standard Treatment
Multiple Myeloma, Relapsed
Light Chain Amyloidosis
Intervention:
BIOLOGICAL: HBI0101 CART
HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric an...